A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303.

ABSTRACT:

Background and aims

Cancer and Leukemia Group B 80303 was a randomized, phase III study in patients with advanced pancreatic cancer treated with gemcitabine plus either bevacizumab or placebo. We prospectively collected germline DNA and conducted a genome-wide association study (GWAS) using overall survival (OS) as the endpoint.

Experimental design

DNA from 351 patients was genotyped for more than 550,000 single-nucleotide polymorphisms (SNP). Associations between OS and SNPs were investigated using the log-linear 2-way multiplicative Cox proportional hazards model. The subset of 294 genetically European patients was used for the primary analysis.

Results

A nonsynonymous SNP in interleukin (IL)17F (rs763780, H161R) and an intronic SNP in strong linkage disequilibrium

SUBMITTER: Innocenti F 

PROVIDER: S-EPMC3412624 | biostudies-literature | 2012 Jan

REPOSITORIES: biostudies-literature